SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
{1} Release: Initial Data Released From Phase III ECOG 4494 Study Of Rituxan As Front-Line And Maintenance Therapy In Aggressive Non-Hodgkin's Lymphoma; Early Drug Data Fails To Show Survival When Given As Maintenance Therapy